Elicio Therapeutics awards 21,750 options to director

Elicio Therapeutics granted director Julian Adams a 21,750-share stock option as his 2026 annual non-employee director equity award.

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. (ELTX) reported that director Julian Adams received a stock option grant for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.

The award is the annual non-employee director equity grant and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to his continued service. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 21,750 shares

Grant/Award 1 txn

Insider ADAMS JULIAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	21,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,750 contracts (Direct)

Footnotes (1)

1. F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Key Figures

Stock options granted: 21,750 options Exercise price: $2.70 per share Expiration date: August 31, 2036 +2 more

5 metrics

Stock options granted 21,750 options Annual non-employee director equity award granted August 31, 2026

Exercise price $2.70 per share Exercise price of stock options granted to Julian Adams

Expiration date August 31, 2036 Expiration of stock options granted August 31, 2026

Shares underlying options 21,750 shares Common stock underlying the stock option grant

Shares held in option after transaction 21,750 options Total derivative securities held directly by Julian Adams after this grant

Key Terms

Stock Option, exercise price, vesting, non-employee director equity award

4 terms

Stock Option financial

"The stock option represents the annual non-employee director equity award"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion or exercise price of the option is $2.7000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shall vest and become exercisable in full on the earlier of (A) August 31, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

non-employee director equity award financial

"represents the annual non-employee director equity award to the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Elicio Therapeutics (ELTX) grant to director Julian Adams?

Elicio Therapeutics granted Julian Adams a stock option for 21,750 shares of common stock on August 31, 2026 as his annual non-employee director equity award.

What is the exercise price of Julian Adams’ new ELTX stock options?

The stock options granted to Julian Adams have an exercise price of $2.70 per share, allowing him to buy Elicio Therapeutics common stock at that price once the options vest and become exercisable.

When do Julian Adams’ ELTX stock options vest and become exercisable?

The options will vest and become exercisable in full on the earlier of August 31, 2027 or the 2027 annual meeting of stockholders, provided he continues to provide services to Elicio Therapeutics through that vesting date.

When do Julian Adams’ ELTX stock options expire?

The stock options granted to Julian Adams expire on August 31, 2036, giving him a 10-year term from the August 31, 2026 grant date to exercise vested options.

Will Julian Adams receive another ELTX equity award for the 2026 annual meeting?

No. The filing states that no additional equity award will be made to Julian Adams in connection with the 2026 annual meeting of stockholders; this grant represents his annual non-employee director equity award.

Were Julian Adams’ ELTX transactions made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan for this transaction, meaning the grant is reported as a standard equity award rather than under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAMS JULIAN

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.7	08/31/2026		A		21,750		(1)	08/31/2036	Common Stock	21,750	$0	21,750	D

Explanation of Responses:

1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Remarks:

	/s/ Julian Adams	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)